FINANCIAL PERFORMANCE

  • Consolidated operating revenue increased 10% YoY to Rs 4,336 crore, driven by strong growth in the Biopharma business.
  • Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.

             o              Biosimilars revenue increased 16% YoY to Rs 2,855 crore.

             o              Generics revenue increased 21% YoY Rs 760 crore.

  • Services revenue decreased 16% YoY to Rs 736 crore due to continued impact of challenges faced last year.
  • Consolidated EBITDA stood at Rs 902 crore, with a margin of 21%, supported by improved profitability in the Biopharma business, which helped offset continued challenges in the Services business.
  • Interest cost at Rs 213 crore, down 23% YoY from Rs 277 crore, following the actions taken to strengthen Biocon’s balance sheet.
  • Net Profit before exceptionals was Rs 145 crore.

LEADERSHIP COMMENTS

“Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth.”

 – Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited

“Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya™️ and Aukelso™️ (biosimilar Denosumab), Yesafili™️ (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. We also secured regulatory approval from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.”

– Shreehas Tambe, CEO & Managing Director, Biocon Limited

“As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth.

My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation and differentiated scientific capabilities that will strengthen our competitive position.” 

– Siddharth Mittal, CEO & Managing Director, Syngene International Limited 

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q1FY27

In Rs Crore

ParticularsQ1FY27Q1FY26YoY (%)
INCOME   
Biosimilars2,8552,45816%
Generics760  63021%
Biopharma (Biosimilars + Generics)3,6153,08817%
Services736875(16%)
Inter-segment(15)(21)28%
Revenue from operations#4,3363,94210%
Other income5580(31%)
Total Income4,3914,0229%
Net R&D Expenses24020517%
EBITDA9028467%
EBITDA Margins21%21% 
PBT (before Exceptional items)14111424%
PBT (after Exceptional items^)1289732%
Net Profit (before Exceptional Items^^)14542245%
Net Profit (Reported)14131355%

Figures above are rounded off to the nearest Crore; % based on absolute numbers.

Notes to financials above: 

#Revenue from operations includes licensing income

^Exceptional items during Q1FY27 and Q1FY26 amount to Rs (13) crore and Rs (17) crore, respectively

^^Net of tax and minority interest, exceptional items during Q1FY27 and Q1FY26 amounted to Rs. (4) crore and Rs. (11) crore respectively, resulting in a Net Profit of Rs 141 crore and Rs 31 crore, respectively